Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

被引：0
|
作者：
Leong, Sally
Ali, Sana
Zengin, Zeynep Busra
Meza, Luis A.
Dizman, Nazli
Ebrahimi, Hedyeh
Govindarajan, Ameish
Castro, Daniela V.
Li, Xiaochen
Kim, Tane
Melamed, Sam
Pal, Sumanta Monty
Chehrazi-Raffle, Alex
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Lundquist Res Inst, Torrance, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
613
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
    Gul, Anita
    Shah, Neil J.
    Mantia, Charlene
    Hammers, Hans J.
    Ornstein, Moshe Chaim
    McDermott, David F.
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).
    Grewal, Kabir
    Chauhan, Pankaj Kumar
    Mukhida, Sagar S.
    Tannir, Nizar M.
    Venkatesh, Neha
    Shah, Amishi Yogesh
    Zurita, Amado J.
    Johns, Andrew
    Campbell, Matthew T.
    Goswami, Sangeeta
    Gao, Jianjun
    Jonasch, Eric
    Mcquade, Jennifer Leigh
    Alhalabi, Omar
    Msaouel, Pavlos
    Hahn, Andrew Warren
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545
  • [3] Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).
    George, Laeth
    Wei, Wei
    Diaz-Montero, C. Marcela
    Martin, Allison
    Vyas, Neil
    Basu, Arnab
    Beckermann, Katy
    Nizam, Amanda
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Gupta, Shilpa
    Rini, Brian I.
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
    Ali, Sana
    Leong, Sally
    Meza, Luis A.
    Dizman, Nazli
    Zengin, Zeynep Busra
    Kim, Tane
    Pak, Youngju
    Onyshchenko, Mykola
    Pal, Sumanta K.
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).
    Lemelin, Audreylie
    Takemura, Kosuke
    Ernst, Matthew Scott
    Wells, J. Connor
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Davis, Ian D.
    Wood, Lori
    Pal, Sumanta Kumar
    Hansen, Aaron Richard
    Kollmannsberger, Christian K.
    Bjarnason, Georg A.
    Tran, Ben
    Li, Haoran
    Kanesvaran, Ravindran
    Powles, Thomas
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [7] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [8] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] A pilot randomized study evaluating nivolumab (nivo) or nivo plus bevacizumab (bev) or nivo plus ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
    Gao, Jianjun
    Karam, Jose A.
    Tannir, Nizar M.
    Campbell, Matthew T.
    Tidwell, Rebecca Slack
    Ahrar, Kamran
    Rao, Priya
    Ng, Chaan S.
    Jonasch, Eric
    Matin, Surena F.
    Zurita, Amado J.
    Shah, Amishi Yogesh
    Shen, Yu
    Blando, Jorge M.
    Vence, Luis M.
    Basu, Sreyashi
    Zhao, Hao
    Allison, James Patrick
    Wood, Christopher G.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345